In regards to biotech’s bullish year, the author of today’s article notes that “The COVID-19 pandemic has put a fire under many lesser-known names, including companies researching compounds and therapeutics not directed at defeating the virus. Many of these issues will close near all-time highs on Dec. 31, perfectly positioned for additional 2021 upside.” He proceeds to highlight three such high-flying biotech stocks that are currently in the mid-cap “sweet spot”. For more, CLICK HERE.